Thrombocytopenia Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Prevalence, NDA Approval, Incidence, Therapies, and Companies by DelveInsight
Thrombocytopenia Companies such as Sanofi, Principia Biopharma, Baxalta, Takeda, Argenx, Millennium Pharmaceuticals, Biotest, GC Pharma, Genosco (Subsidiary of Oscotec), Rigel Pharmaceuticals, Kissei Pharmaceutical, Shionogi & Co., Ltd, Amgen, Novartis, Zenyaku Kogyo and others.
(Albany, USA) DelveInsight's ' Thrombocytopenia Market Insights, Epidemiology and Market Forecast – 2034 ' report delivers an in-depth understanding of thrombocytopenia, historical and forecasted epidemiology as well as the thrombocytopenia market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
The Thrombocytopenia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Thrombocytopenia market size from 2020 to 2034, segmented by seven major markets. The Thrombocytopenia Market Report also covers current Thrombocytopenia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Thrombocytopenia market.
Explore the intricate details of the Thrombocytopenia Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Thrombocytopenia Market Forecast. Click here to stay ahead in healthcare innovation @ Thrombocytopenia Market Size
Key Takeaways from the Thrombocytopenia Market Report
The United States accounts for the largest market size (around 60%) of thrombocytopenia, in comparison to EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
Among all cases of thrombocytopenia in the United States, the largest group consists of those with heparin-induced thrombocytopenia followed by chronic liver disease.
DelveInsight's consultant estimates that the United States accounts for approximately 20% of total cases of Thrombocytopenia in Chronic Liver Disease, in the 7MM.
The United States had the highest cases of thrombotic thrombocytopenia compared to EU4 and the UK and Japan, as assessed in 2023.
The leading Thrombocytopenia Companies such as Sanofi, Principia Biopharma, Baxalta, Takeda, Argenx, Millennium Pharmaceuticals, Biotest, GC Pharma, Genosco (Subsidiary of Oscotec), Rigel Pharmaceuticals, Kissei Pharmaceutical, Shionogi & Co., Ltd, Amgen, Novartis, Zenyaku Kogyo and others.
Promising Thrombocytopenia Therapies such as VLX-1005, Herombopag, Avatrombopag Oral Tablet, Rilzabrutinib, Selinexor 60 mg, Nipocalimab, QL0911, and others.
June 2024:- Qidong Gaitianli Medicines Co., Ltd- A Multisite, Randomized, Double-Blind, Placebo-Controlled, and Parallel Study to Evaluate the Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia (Qi Yin Deficiency).
June 2024:- Karyopharm Therapeutics Inc.- A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia. The main purpose of this study with corresponding optional expansion is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy and safety parameters will also be assessed during the study.
June 2024:- Janssen Research & Development LLC- Double-blind, Randomized, Placebo-controlled Study Evaluating the Safety and Efficacy of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) in At-risk Pregnancies. The purpose of this study is to evaluate the effectiveness of nipocalimab compared with placebo in reducing the risk of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
June 2024:- Amgen- A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer.
June 2024:- Qilu Pharmaceuticals Ltd- Phase 2/3 Randomized, Double-blind, Placebo-controlled Study of QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia. To evaluate the efficacy and safety of QL0911 in cancer treatment-induced thrombocytopenia. Thrombocytopenia is a low number of platelets in the blood. Sometimes, thrombocytopenia is a side effect of cancer treatment.
Navigate the complexities of the Thrombocytopenia Market: Gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Thrombocytopenia Market Forecast. Click here to get more insights @ Thrombocytopenia Treatment Market
Thrombocytopenia Epidemiology Segmentation in the 7MM
Total Thrombocytopenia Cases
Total Cases of Immune Thrombocytopenia
Total Cases of Thrombocytopenia in Chronic Liver Disease
Total Cases of Chemotherapy-induced Thrombocytopenia
Total Number of Cases of Heparin-induced Thrombocytopenia
Total Thrombocytopenia Cases
Delve deep into the Thrombocytopenia Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Thrombocytopenia Market Forecast. Click here to shape the future @ Thrombocytopenia Prevalence
Thrombocytopenia Marketed Drugs
• ADZYNMA: Takeda
ADZYNMA (ADAMTS13, recombinant-krhn) is a human recombinant (a disintegrin and metalloproteinase with thrombospondin motifs 13) ADAMTS13 (rADAMTS13) indicated for prophylactic or on-demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP). ADZYNMA was previously granted Orphan Drug Designation (ODD) by the US FDA for the treatment and prevention of TTP, including its acquired idiopathic and secondary forms, as well as Fast Track and Rare Pediatric Disease Designation. The US FDA also granted Takeda a Rare Pediatric Disease Voucher for the approval of ADZYNMA. ADZYNMA has also been granted ODD by the European Medicines Agency (EMA) and Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of TTP.
• TAVALISSE (fostamatinib): Rigel Pharmaceuticals/Kissei Pharmaceutical
Fostamatinib disodium (also known as TAVALISSE; R-985788) is an orally-bioavailable investigational agent being developed by Rigel pharmaceuticals and approved for the treatment of patients suffering from persistent/chronic adult idiopathic thrombocytopenic purpura. The therapeutic candidate inhibits FcR-triggered, Syk-dependent cytoskeletal rearrangement during phagocytosis.
Thrombocytopenia Emerging Drugs
• Rilzabrutinib (PRN-1008): Sanofi/Principia Biopharma
Rilzabrutinib (PRN-1008) is an orally administered reversible covalent inhibitor of Bruton tyrosine kinase (BTK). BTK is an essential signaling element downstream of the B-cell receptor (BCR), Fc-gamma receptor, and Fc-epsilon receptor pathways. Rilzabrutinib is currently being evaluated in the Phase III stage of development to treat ITP in adults and adolescents with persistent or chronic ITP. Recently, the LUNA 3 Phase III study showed that rilzabrutinib at a dose of 400 mg twice daily orally successfully met the primary endpoint of achieving a durable platelet response in adult patients with persistent or chronic immune thrombocytopenia (ITP). The safety profile observed for rilzabrutinib in this study was consistent with previous findings from other studies.
Thrombocytopenia Market Insights
Thrombocytopenia is a condition in which the blood has a lower than the normal platelet count. When a patient's blood has too few platelets, mild to serious bleeding can occur. Bleeding can be internal or underneath the skin, or external. The approved therapies for treating thrombocytopenia in the US include MULPLETA, DOPTELET,TAVALISSE, PROMACTA, NPLATE, CABLIVI, GAMMAPLEX, OCTAGAM, RHOPHYLAC, and PRIVIGEN. These therapies are approved for various patient groups; for example, MULPLETA and DOPTELET are approved for thrombocytopenia in chronic liver disease, PROMACTA is approved for chronic immune (idiopathic) thrombocytopenic purpura (ITP).
Thrombocytopenia Treatment Landscape
Treatment for thrombocytopenia depends on its cause and severity. The main goal of treatment is to prevent death and disability caused by bleeding. The approved therapies for treating thrombocytopenia in the US include MULPLETA, DOPTELET, TAVALISSE, PROMACTA, NPLATE, CABLIVI, GAMMAPLEX, OCTAGAM, RHOPHYLAC, and PRIVIGEN. Danaparoid, argatroban, and lepirudin were approved in the US to treat thrombosis in patients with heparin-induced thrombocytopenia. Current treatment options for severe thrombocytopenia in chronic liver disease include platelet transfusion, splenic artery embolization, splenectomy, and placement of a transjugular intrahepatic portosystemic stent shunt (TIPSS).
Gain a strategic edge in the Thrombocytopenia Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Thrombocytopenia Market Forecast. Click here to lead in advancements @ Thrombocytopenia Clinical Trials Assessment
Scope of the Thrombocytopenia Market Report
Coverage- 7MM
Thrombocytopenia Companies- Sanofi, Principia Biopharma, Baxalta, Takeda, Argenx, Millennium Pharmaceuticals, Biotest, GC Pharma, Genosco (Subsidiary of Oscotec), Rigel Pharmaceuticals, Kissei Pharmaceutical, Shionogi & Co., Ltd, Amgen, Novartis, Zenyaku Kogyo and others.
Thrombocytopenia Therapies- VLX-1005, Herombopag, Avatrombopag Oral Tablet, Rilzabrutinib, Selinexor 60 mg, Nipocalimab, QL0911, and others.
Thrombocytopenia Market Dynamics: Thrombocytopenia Market drivers and Thrombocytopenia Market Barriers
Thrombocytopenia Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Thrombocytopenia Unmet Needs, KOL's views, Analyst's views, Thrombocytopenia Market Access and Reimbursement
Table of Content
1. Key Insights
2. Report Introduction
3. Thrombocytopenia Market Overview at a Glance
4. Executive Summary of Thrombocytopenia
5. Key events
6. Thrombocytopenia Market Disease Background and Overview
7. Thrombocytopenia Methodology
8. Thrombocytopenia Epidemiology and Patient Population
9. Patient Journey
10. Thrombocytopenia Marketed Products
11. Thrombocytopenia Emerging Therapies
12. Thrombocytopenia Seven Major Market Analysis
13. Market Access and Reimbursement
14. KOL Views
15. Thrombocytopenia Unmet Needs
16. SWOT Analysis
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/pipeline-assessment-services
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
a day ago
- Globe and Mail
Kidney Transplant Rejection Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight
DelveInsight's 'Kidney Transplant Rejection Market Insights, Epidemiology, and Market Forecast – 2034' report delivers an in-depth understanding of kidney transplant rejection, historical and forecasted epidemiology, as well as the kidney transplant rejection therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. Unlock key insights into the Kidney Transplant Rejection Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Kidney Transplant Rejection Market Size Key Takeaways from the Kidney Transplant Rejection Market Report In June 2025, Biogen announced a clinical trial is to evaluate the efficacy of felzartamab compared to placebo in kidney transplant recipients diagnosed with late active or chronic active AMR. In June 2025, Tract Therapeutics Inc. organized a Phase 2 trial is to determine the safety and efficacy of administering expanded regulatory T cells (TRK-001) to prevent allograft rejection in living donor renal transplant recipients. In 2023, there were an estimated 44 thousand total incident cases of kidney transplants across the 7MM, with the number expected to rise by 2034. According to DelveInsight's estimates, there were approximately 27 thousand incident cases of kidney transplants across the US in 2023, with the number expected to rise by 2034. In 2023, the US reported approximately 2 thousand acute and 8 thousand chronic cases of kidney transplant rejection, with these numbers expected to increase by 2034. In 2023, among EU4 and the UK, the UK reported the highest number of living kidney transplants, with approximately 46 thousand instances, followed by France, with nearly 45 thousand cases. In contrast, Italy recorded the lowest, with around 28 thousand cases. In 2023, EU4 and the UK reported approximately 2 thousand acute and 4 thousand chronic cases of kidney transplant rejection. By 2034, these numbers are expected to increase to nearly 4 thousand acute cases and 7 thousand chronic cases. In 2023, Japan had approximately 2 thousand incident cases of kidney transplants. This number is projected to rise by 2034, growing at a CAGR of 0.7%. The leading Kidney Transplant Rejection Companies such as Amgen Inc, Amyndas Pharmaceuticals LLC, Astellas Pharma Inc, Bristol-Myers Squibb Co, Alphamab Oncology, AltruBio Inc, Cynata Therapeutics Ltd, Eledon Pharmaceuticals Inc, Enceladus Pharmaceuticals BV, Hansa Biopharma AB, Helocyte Bi, and others. Promising Kidney Transplant Rejection Pipeline Therapies such as Sonazoid, Belatacept, VIB4920, Thymoglobulin, AT-1501, Tacrolimus, Simulect, Belimumab and others. Stay ahead in the competitive landscape of the Kidney Transplant Rejection Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Kidney Transplant Rejection Treatment Market Size Kidney Transplant Rejection Epidemiology Segmentation in the 7MM Total Kidney Transplant Rejection Incident Cases Total Kidney Transplant Rejection Living Cases Kidney Transplant Rejection Type-specific Cases Download the report to understand which factors are driving Kidney Transplant Rejection epidemiology trends @ Kidney Transplant Rejection Prevalence Marketed Kidney Transplant Rejection Prophylaxis Drugs MYHIBBIN: Azurity Pharmaceuticals MYHIBBIN, developed by Azurity Pharmaceuticals, is the first ready-to-use mycophenolate mofetil (MMF) oral suspension approved for preventing organ rejection in patients aged 3 months and older who have received allogeneic kidney, heart, or liver transplants. Approved by the US FDA in May 2024, MYHIBBIN is intended for use in combination with other immunosuppressive therapies. The product works by inhibiting inosine monophosphate dehydrogenase (IMPDH), a key enzyme in the de novo guanosine nucleotide synthesis pathway, leading to the suppression of T and B lymphocyte proliferation and cytokine production, which prevents graft rejection. THYMOGLOBULIN: Sanofi THYMOGLOBULIN, developed by Sanofi, is an immunosuppressive therapy derived from rabbit serum through immunization with human thymocytes. This purified, pasteurized IgG product targets T lymphocyte antigens and is designed for the prevention of acute kidney transplant rejection. Administered via intravenous infusion, it exerts therapeutic effects by clearing circulating T cells and modulating their activation, homing, and cytotoxic functions. Its mechanism includes targeting multiple T-cell markers, such as CD2, CD3, CD4, and HLA-DR, promoting immune suppression and reducing the risk of transplant rejection. NULOJIX: Bristol Myers Squibb NULOJIX (belatacept), developed by Bristol Myers Squibb, is a selective T-cell costimulation blocker approved for the prevention of organ rejection in adult kidney transplant recipients. Administered via intravenous infusion, NULOJIX is used alongside basiliximab induction, mycophenolate mofetil, and corticosteroids. Its mechanism of action involves targeting CD80 and CD86 on antigen-presenting cells, thereby preventing CD28-mediated T-cell activation, a key driver of immunologic rejection. This results in reduced T-cell proliferation and cytokine production, including interleukin-2 and TNF-a, mitigating the immune response in transplant rejection. Emerging Kidney Transplant Rejection Drugs MDR-101: Medeor Therapeutics MDR-101, developed by Medeor Therapeutics, is an innovative cellular therapy derived from the blood and peripheral stem cells of a living kidney donor. The therapy is designed to induce donor-specific immune tolerance, effectively preventing kidney transplant rejection. By reprogramming the recipient's immune system to accept the donor organ, MDR-101 eliminates the need for lifelong immunosuppressive drugs and their associated side effects, thereby enhancing transplant kidney function and long-term survival. Positive interim data from a Phase III trial, presented as a late-breaking oral presentation at the American Society of Nephrology (ASN) Kidney Week in November 2023, highlighted its potential as a breakthrough in transplantation medicine. MDR-101 has received ODD in both the US and EU. The clinical trial is being conducted under an FDA Special Protocol Assessment (SPA). In September 2020, the US FDA also granted Regenerative Medicine Advanced Therapy (RMAT) designation to MDR-101 for the prevention of kidney transplant rejection. Further, in January 2018, the California Institute for Regenerative Medicine (CIRM) awarded USD 18.8 million to support the Phase III clinical trial under its clinical trial funding initiative. Tegoprubart (AT-1501): Eledon Pharmaceuticals Tegoprubart, developed by Eledon Pharmaceuticals, is a humanized monoclonal antibody targeting the CD40L pathway, designed to prevent kidney transplant rejection by blocking the CD40-CD40L interaction. This innovative immunosuppressive therapy aims to replace traditional calcineurin inhibitors (CNIs), such as tacrolimus, potentially improving long-term graft survival and patient outcomes. In September 2024, Eledon completed enrollment for the Phase II BESTOW trial, four months ahead of schedule, with topline results anticipated in Q4 2025. Phase Ib trial data presented at the American Transplant Congress (ATC) in June 2024 demonstrated the drug's safety and tolerability. Riliprubart (BIVV020, SAR445088): Sanofi Riliprubart, developed by Sanofi, is an IgG4 humanized monoclonal antibody under investigation for the treatment of Antibody-Mediated Rejection (AMR) in kidney transplants. The drug works by selectively inhibiting activated complement component C1s, a critical mediator of the inflammatory processes associated with AMR. Phase II clinical trials are currently underway to evaluate the efficacy and safety of Riliprubart in patients diagnosed with or at risk of AMR. Administered intravenously, Riliprubart represents a promising therapeutic approach to addressing AMR in kidney transplant recipients. Discover the future of Kidney Transplant Rejection Treatments with DelveInsight's latest market report. Get expert insights and forecasts—download now! @ Kidney Transplant Rejection Market Drivers and Barriers Kidney Transplant Rejection Market Outlook Kidney transplant rejection is a major concern for recipients, as it can severely affect the long-term success and function of the transplanted organ. Rejection happens when the recipient's immune system recognizes the donor kidney as foreign, prompting an immune response that damages the graft. There are two main types of rejection: Acute, which usually occurs within the first-year after transplantation, and chronic, which develops gradually over several years and is more prevalent. Chronic rejection is often associated with insufficient immunosuppression or non-compliance with medication regimens, leading to ongoing immune attacks that result in scarring and eventual loss of kidney function. Around 15–20% of transplant recipients experience some form of rejection, highlighting the importance of regular monitoring and strict adherence to immunosuppressive therapy to reduce this risk. Kidney Transplant Rejection Drugs Market Insights Currently, a variety of medication approaches for kidney transplant rejection prophylaxis involve approved treatments that utilize different mechanisms of action to support long-term transplant success. These include ENVARSUS XR, IDEFIRIX, NULOJIX, THYMOGLOBULIN, MYHIBBIN, and SIMULECT, among others, all of which play a crucial role in managing immune responses and minimizing the risk of rejection. Kidney transplant rejection aims to manage immune responses, prevent further organ damage, and ensure long-term transplant success. Treatment involves a combination of immunosuppressive therapies, close monitoring, and supportive care to address acute and chronic rejection. Key goals include preserving graft function, reducing inflammation, minimizing complications, and improving the patient's quality of life. Lifestyle adjustments, including dietary management and adherence to medication regimens, are essential for long-term success. While challenges remain, ongoing research is focused on advancing therapies to enhance graft survival and improve outcomes for transplant recipients. Explore the dynamics of the Kidney Transplant Rejection Market with DelveInsight. From market size to emerging drugs—find it all in our latest report. Read now! @ Kidney Transplant Rejection Ongoing Clinical Trials Analysis Scope of the Kidney Transplant Rejection Market Report Coverage- 7MM Study Period- 2020-2034 Kidney Transplant Rejection Companies- Amgen Inc, Amyndas Pharmaceuticals LLC, Astellas Pharma Inc, Bristol-Myers Squibb Co, Alphamab Oncology, AltruBio Inc, Cynata Therapeutics Ltd, Eledon Pharmaceuticals Inc, Enceladus Pharmaceuticals BV, Hansa Biopharma AB, Helocyte Bi, and others. Kidney Transplant Rejection Pipeline Therapies- Sonazoid, Belatacept, VIB4920, Thymoglobulin, AT-1501, Tacrolimus, Simulect, Belimumab and others. Kidney Transplant Rejection Therapeutic Assessment: Kidney Transplant Rejection Current Marketed and Kidney Transplant Rejection Emerging Therapies Kidney Transplant Rejection Market Dynamics: Kidney Transplant Rejection market drivers and Kidney Transplant Rejection market barriers Kidney Transplant Rejection Unmet Needs, KOL's views, Analyst's views, Kidney Transplant Rejection Market Access and Reimbursement Table of Contents 1. Key Insights 2. Report Introduction 3. Market Overview at a Glance 4. Executive Summary 5. Key Events 6. Disease Background and Overview 7. Methodology 8. Epidemiology and Patient Population 9. Patient Journey 10. Marketed Drugs 11. Emerging Drugs 12. Kidney Transplant Rejection – 7MM Market Analysis 13. KOL Views 14. Unmet Needs 15. SWOT Analysis 16. Market Access and Reimbursement 17. Appendix 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
2 days ago
- Globe and Mail
Bronchiectasis Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Therapies, Companies by DelveInsight
"Bronchiectasis Treatment Market" Bronchiectasis Companies are Insmed, AstraZeneca, Zambon, Renovion, Haisco Pharmaceutical Group, Chiesi Farmaceutici S.p.A, Armata Pharmaceuticals, Verona Pharma, Sanofi, Regeneron Pharmaceuticals, Boehringer Ingelheim, CSL, and others. (Albany, USA) DelveInsight's ' Bronchiectasis Market Insights, Epidemiology, and Market Forecast – 2034 ' report delivers an in-depth understanding of bronchiectasis, historical and forecasted epidemiology, as well as the bronchiectasis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. The latest healthcare forecast report provides an in-depth analysis of Bronchiectasis, offering comprehensive insights into the Bronchiectasis revenue trends, prevalence, and treatment landscape. The report delves into key Antiphospholipid Syndrome statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Bronchiectasis therapies. Additionally, we cover the landscape of Bronchiectasis clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Bronchiectasis treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Bronchiectasis space. Key Takeaways from the Bronchiectasis Market Report Bronchiectasis Market Size in the 7MM was ~USD 1,581.2 million in 2023, estimated DelveInsight In November 2024:- Sanofi-A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis. ACT18018 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 study with 3 treatment groups. The purpose of this study is to evaluate efficacy, safety and tolerability with 2 dosing regimens of itepekimab compared with placebo in male and/or female participants with NCFB aged 18 years of age up to 85 years of age (inclusive). In November 2024:- Boehringer Ingelheim- This study is open to adults aged 18 years and older with bronchiectasis. People can join the study if they were previously enrolled in another study with BI 1291583 (1397-0012: Airleafᵀᴹ or 1397-0013 Clairaflyᵀᴹ). The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis, an inflammatory lung condition. The investigators also want to know how well people with this condition can tolerate BI 1291583 in the long term. In November 2024:- Verona Pharma PLC- This study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily via standard jet nebulizer over at least 24 weeks, compared to placebo, in subjects with non-cystic fibrosis bronchiectasis (NCFBE). According to DelveInsight's epidemiology model, in the 7MM, the total diagnosed prevalent cases of NCFB were approximately 1,028,651 in 2023. This number is anticipated to rise during the forecast period (2024-2034), driven by increased awareness and screening, along with advancements in diagnostic techniques. In 2023, the US accounted for the highest number of diagnosed prevalent cases of NCFB, with approximately 380,711 cases, while France accounted for the least, with only 37,576 cases. Among EU4 and the UK, the UK accounted for the highest number of diagnosed prevalent cases of NCFB, with approximately 224,976 cases in 2023, followed by Spain with approximately 149,236 cases, and Italy with nearly 89,584 cases. Among the severity-specific diagnosed prevalent cases of NCFB in EU4 and the UK in 2023, there were approximately 235,481 moderate cases, around 163,649 severe cases, and 152,230 mild cases. Among the gender-specific cases of NCFB in the UK in 2023, there were approximately 130,486 cases for females and around 94,490 cases for males. In Japan in 2023, the majority of etiology-specific diagnosed prevalent cases of NCFB were attributed to other pathogen, accounting for 46,600 cases. In 2023, among the 7MM, Japan had approximately 96,580 diagnosed prevalent cases of NCFB. In 2023, among the 7MM, the US accounted for the highest number of diagnosed prevalent cases of cystic fibrosis bronchiectasis, with approximately 41,566 cases, while Japan accounted for the least, with only 59 cases. Among the gender-specific cases of cystic fibrosis bronchiectasis in EU4 and the UK in 2023, there were approximately 17,081 cases for females and around 18,738 cases for males. Among the age-specific cases of cystic fibrosis bronchiectasis in Japan in 2023, there were approximately 24 cases for children and around 36 cases for adult. In 2023, the majority of etiology-specific diagnosed prevalent cases of cystic fibrosis bronchiectasis in Japan were attributed to Staphylococcus aureus, accounting for 36 cases. The leading Bronchiectasis Companies such as Insmed, AstraZeneca, Zambon, Renovion, Haisco Pharmaceutical Group, Chiesi Farmaceutici S.p.A, Armata Pharmaceuticals, Verona Pharma, Sanofi, Regeneron Pharmaceuticals, Boehringer Ingelheim, CSL, and others. Promising Bronchiectasis Therapies such as CHF6333, Itepekimab (SAR440340), BI 1291583, Aztreonam lysine, HSK31858, RESP302, and others. Stay ahead in the Bronchiectasis Therapeutics Market with DelveInsight's Strategic Report @ Bronchiectasis Market Outlook Bronchiectasis Epidemiology Segmentation in the 7MM Total diagnosed prevalent cases Gender-specific diagnosed prevalent cases Severity-specific diagnosed prevalent cases Etiology-specific diagnosed prevalent cases Microbiology of NCFB patients, Total diagnosed prevalent cases Gender-specific diagnosed prevalent cases Age-specific diagnosed prevalent cases Microbiology of cystic fibrosis bronchiectasis Download the report to understand which factors are driving Bronchiectasis epidemiology trends @ Bronchiectasis Prevalence Bronchiectasis Emerging Drugs Brensocatib: Insmed/AstraZeneca Brensocatib, an oral small-molecule inhibitor targeting dipeptidyl peptidase 1 (DPP1), is being developed by Insmed for the treatment of bronchiectasis, CRSsNP, and other neutrophil-driven conditions. By inhibiting DPP1, brensocatib aims to reduce inflammation by blocking the activation of neutrophil serine proteases (NSPs), such as neutrophil elastase, during neutrophil formation in the bone marrow. Insmed reported positive topline results from the Phase III ASPEN study of brensocatib in patients with bronchiectasis, leading to plans for a New Drug Application (NDA) submission to the US FDA in late 2024. If approved, brensocatib is expected to launch in the US by mid-2025, followed by launches in Europe and Japan in the first half of 2026. In October 2024, Insmed shared positive late-breaking subgroup data from the Phase III ASPEN study of brensocatib for patients with bronchiectasis at the CHEST 2024 Annual Meeting. Furthermore, the EMA approved a Pediatric Investigational Plan for brensocatib in bronchiectasis patients, and brensocatib has gained access to the PRIME scheme and Breakthrough Therapy Designation for adult bronchiectasis patients. Inhaled Colistimethate Sodium (CMS I-neb): Zambon CMS I-neb is an investigational inhaled therapy for adults with bronchiectasis colonized by P. aeruginosa, potentially offering a first-in-class treatment option. It uses colistimethate sodium, a prodrug of colistin, a polymyxin antibiotic targeting aerobic Gram-negative pathogens, including drug-resistant P. aeruginosa. By disrupting the bacterial cell membrane, colistin causes cell death and serves as a last-resort treatment for infections like carbapenem-resistant P. aeruginosa. In September 2024, Zambon released the results of the Phase III PROMIS-I and PROMIS-II studies in The Lancet Respiratory Medicine journal. The Phase III PROMIS-I trial demonstrated a significant reduction in pulmonary exacerbation rates. Although the PROMIS-II trial was terminated early due to the pandemic, pre-pandemic data showed consistency with PROMIS-I outcomes. Zambon is working with regulatory authorities to expedite patient access. The US FDA has granted CMS I-neb Breakthrough Therapy Designation (BTD), as well as QIDP and Fast Track Designation (FTD). FASENRA (benralizumab): AstraZeneca FASENRA (benralizumab) is a monoclonal antibody that targets the IL-5 receptor alpha on eosinophils, facilitating the recruitment of natural killer cells to induce apoptosis, resulting in rapid and near-complete depletion of blood and tissue eosinophils in most patients. FASENRA is currently under investigation for treating adult patients with NCFB associated with eosinophilic inflammation (bronchiectasis + EI). According to FASENRA completed Phase III clinical trials for this indication in April 2024. Bronchiectasis Treatment Market The treatment of bronchiectasis involves several drug classes tailored to manage symptoms, reduce exacerbations, and control underlying inflammation. Antibiotics, both oral and inhaled, are essential for managing chronic bacterial colonization, particularly against pathogens like P. aeruginosa. Macrolides, often used for their anti-inflammatory properties, are beneficial in reducing exacerbation frequency. Bronchodilators, including beta-agonists and anticholinergics, help alleviate airway obstruction, while corticosteroids are used to address inflammation, although their role remains limited due to potential side effects. Mucolytic agents improve mucus clearance, and emerging anti-inflammatory agents targeting neutrophilic inflammation, such as DPP1 inhibitors, represent innovative approaches. Together, these drug classes form a comprehensive yet evolving treatment landscape for bronchiectasis, addressing its multifaceted pathophysiology. Bronchiectasis Market Outlook The market for bronchiectasis is poised for significant growth due to the evolving landscape of pharmacological and non-pharmacological interventions addressing the complex pathophysiology of the disease. Current therapeutic strategies encompass a range of treatment options which includes medications, chest physical therapy, hydration, and in severe cases, oxygen therapy with inhaled antibiotics demonstrating efficacy in managing chronic bacterial infections and reducing exacerbation rates. Emerging therapies, such as Brensocatib, a Dipeptidyl Peptidase 1 (DPP1) inhibitor, and BI 1291583, a cathepsin C inhibitor, target neutrophilic inflammation through distinct mechanisms, thereby offering novel approaches to improve patient outcomes. Bronchiectasis Therapeutics Market Additionally, investigational therapies like CMS I-neb and monoclonal antibodies such as FASENRA and Itepekimab present further options by directly targeting specific inflammatory pathways associated with eosinophilic inflammation. The incorporation of non-pharmacological approaches, particularly Airway Clearance Techniques (ACTs), complements pharmacological regimens, enhancing mucus clearance and preventing infection. However, the market faces challenges, including a lack of consensus guidelines and under-researched therapies like mucolytics and hyperosmolar agents, which may hinder optimal patient management. Scope of the Bronchiectasis Market Report Coverage- 7MM Bronchiectasis Companies- Insmed, AstraZeneca, Zambon, Renovion, Haisco Pharmaceutical Group, Chiesi Farmaceutici S.p.A, Armata Pharmaceuticals, Verona Pharma, Sanofi, Regeneron Pharmaceuticals, Boehringer Ingelheim, CSL, and others. Bronchiectasis Therapies- CHF6333, Itepekimab (SAR440340), BI 1291583, Aztreonam lysine, HSK31858, RESP302, and others. Bronchiectasis Therapeutic Assessment: Bronchiectasis Current marketed and Lipodystrophy Emerging Therapies Bronchiectasis Market Dynamics: Bronchiectasis Market drivers and Bronchiectasis Market Barriers Table of Content 1. Key Insights 2. Report Introduction 3. Market Overview at a Glance 4. Epidemiology and Market Forecast Methodology 5. Executive Summary 6. Key Events 7. Disease Background and Overview 8. Patient Journey 9. Epidemiology and Patient Population 10. Emerging Drugs 11. Bronchiectasis: Market Analysis 12. Key Opinion Leaders' Views 13. SWOT Analysis 14. Unmet Needs 15. Market Access and Reimbursement 16. Appendix 17. DelveInsight Capabilities 18. Disclaimer 19. About DelveInsight About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
Globe and Mail
2 days ago
- Globe and Mail
Acne Vulgaris Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Therapies, Epidemiology, Revenue, Statistics, Medication, and Companies by DelveInsight
Acne Vulgaris Companies are BioPharmX, Bausch Health Americas, Inc., Kintor Pharma, Sol-Gel Technologies, Ltd., Ascletis Pharma, Galderma R&D, Torrent Pharma, Dermata Therapeutics, Clinuvel Pharma, Novan, Inc., Dermata Therapeutics, Accelovance, Balmoral Medical, Vyne Therapeutics Inc., XOMA (US) LLC, Braintree Laboratories, Teva Pharma, AnaptysBio, Inc., Janssen Research, Cutia Therapeutics, Bausch Health, and others. (Albany, USA) DelveInsight's 'Acne Vulgaris Market Insights, Epidemiology, and Market Forecast – 2034' report delivers an in-depth understanding of the Acne Vulgaris, historical and forecasted epidemiology as well as the Acne Vulgaris therapeutics market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan. The latest healthcare forecast report provides an in-depth analysis of Acne Vulgaris, offering comprehensive insights into the Acne Vulgaris revenue trends, prevalence, and treatment landscape. The report delves into key Acne Vulgaris statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Acne Vulgaris therapies. Additionally, we cover the landscape of Acne Vulgaris clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Acne Vulgaris treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Acne Vulgaris space. Unlock key insights into the Acne Vulgaris Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Acne Vulgaris Market Size Key Takeaways from the Acne Vulgaris Market Report The Acne Vulgaris market size was valued ~USD 4,256 million in 2023 among the 7MM countries and is anticipated to grow with a significant CAGR during the study period (2020-2034) In March 2025, Dermata Therapeutics, Inc. (Nasdaq: DRMA, DRMAW), a late-stage biotechnology company specializing in medical and aesthetic skin disease treatments, has announced the completion of the final patient visit in its pivotal Phase 3 Spongilla Treatment for Acne Research (STAR-1) trial. The trial is evaluating XYNGARITM, a novel once-weekly topical treatment designed for moderate-to-severe acne In March 2025, Kane Biotech Inc. (TSX-V: KNE, OTCQB: KNBIF) has received approval from the Internal Review Board (IRB) of the University of Miami Health System (UHealth) to initiate a clinical study evaluating its DispersinB® Acne Cleanser prototype for treating mild to moderate Acne Vulgaris. In March 2025, Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and fibrotic diseases, has received FDA clearance for its Investigational New Drug (IND) application for TVB-3567, the company's second fatty acid synthase (FASN) inhibitor. This potent and selective small molecule is set to enter clinical development for acne treatment. The IND approval from the FDA's Division of Dermatology and Dentistry paves the way for a first-in-human Phase 1 trial of TVB-3567, expected to begin in 2025. In 2023, the US had the largest market size for Acne Vulgaris among the 7MM, reaching approximately USD 2,949 million, with expectations for further growth by 2034. Among European countries, Germany had the largest Acne Vulgaris Market Size in 2023, reaching USD 311 million, while the UK had the smallest market size, with USD 121 million. In 2023, the Acne Vulgaris Market Size in Japan was approximately USD 316 million, with expectations for continued growth by 2034. In 2023, the 7MM reported around 29,433 thousand diagnosed prevalent cases of Acne Vulgaris, with an anticipated rise in cases throughout the forecast period from 2024 to 2034. In 2023, the 7MM saw an estimated ~140,217 thousand cases of Acne Vulgaris, with the US accounting for around 69,500 thousand cases. These figures are expected to grow consistently over the forecast period. The prevalence of Acne Vulgaris is categorized by age groups: 15-19 years, 20-29 years, 30-39 years, 40-49 years, and 50 years and older. In the United States, the highest number of cases was seen in the 15-19 age group, with approximately 5,853 thousand cases reported in 2023. The upcoming drug SB204 is anticipated to enter the US market by 2027, with the potential to alleviate the burden of acne vulgaris during the forecast period. Key Acne Vulgaris Companies: BioPharmX, Bausch Health Americas, Inc., Kintor Pharma, Sol-Gel Technologies, Ltd., Ascletis Pharma, Galderma R&D, Torrent Pharma, Dermata Therapeutics, Clinuvel Pharma, Novan, Inc., Dermata Therapeutics, Accelovance, Balmoral Medical, Vyne Therapeutics Inc., XOMA (US) LLC, Braintree Laboratories, Teva Pharma, AnaptysBio, Inc., Janssen Research, Cutia Therapeutics, Bausch Health, and others Key Acne Vulgaris Therapies: BPX-01, IDP-120, GT20029, KX-826, S6G5T-3, ASC40, GK530G, Dapsone, DMT310, CD5789 (trifarotene), Afamelanotide, NVN1000, Hydrogen Peroxide, Trifarotene Cream, S6G5T-3, GDC 268 Lotion, Isotretinoin, gevokizumab, BLI1100, AKLIEF®, Imsidolimab, RA-18C3, FMX101, IDP-126, and others The Acne Vulgaris epidemiology based on gender analyzed that females are predominantly affected compared to males The Acne Vulgaris market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acne Vulgaris pipeline products will significantly revolutionize the Acne Vulgaris market dynamics. Stay ahead in the competitive landscape of the Acne Vulgaris Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Acne Vulgaris Treatment Market Size Acne Vulgaris Epidemiology Segmentation in the 7MM Acne Vulgaris Prevalent Cases Acne Vulgaris Diagnosed Prevalent Cases Acne Vulgaris Severity-specific Diagnosed Prevalent Cases Acne Vulgaris Gender-specific Diagnosed Prevalent Cases Acne Vulgaris Age-specific Diagnosed Prevalent Cases Download the report to understand which factors are driving Acne Vulgaris epidemiology trends @ Acne Vulgaris Prevalence Acne Vulgaris Marketed Drugs AKLIEF (Trifarotene)/ CD-5789: Galderma S.A. Trifarotene, a first-in-class fourth-generation topical retinoid, has been approved by the FDA for the treatment of acne vulgaris in patients aged 9 years and older. This novel retinoid selectively targets retinoic acid receptor gamma (RAR?), the most common RAR found in the skin, making it a more targeted and skin-specific treatment compared to earlier-generation retinoids. Trifarotene is effective in reducing inflammatory lesions on the face and trunk, with significant improvements observed as early as 2 weeks on the face and 4 weeks on the back, shoulders, and chest. The cream is well tolerated, with common adverse reactions including application-site irritation, pruritus, and sunburn. AMZEEQ (minocycline): Journey Medical Corporation/Vyne Therapeutics Inc. In 2019, the FDA approved AMZEEQ, a foam formulation of the tetracycline antibiotic minocycline, for treating severe acne in adults and children aged 9 years and older. AMZEEQ is specifically indicated for treating pimples and red bumps (non-nodular inflammatory lesions) linked to moderate to severe acne. This new formulation utilizes Foamix's proprietary Molecule Stabilizing Technology (MST) platform to deliver minocycline in a foam form, offering a more targeted and effective treatment option. Furthermore, minocycline is also approved by the FDA for treating rosacea in adult patients, expanding its therapeutic applications in dermatology. ARAZLO (tazarotene): Bausch Health Companies Inc. / Ortho Dermatologics ARAZLO, a topical cream containing tazarotene as the active ingredient, is a treatment option for acne vulgaris in patients aged 9 years and older. The cream combines tazarotene with three moisturizers: sebacic acid, light mineral oil, and sorbitol, allowing it to be highly effective against acne while minimizing skin irritation. Additionally, ARAZLO lotion employs patented polymeric emulsion technology, which enhances skin absorption and reduces irritation, making it a comprehensive treatment option for acne patients. Acne Vulgaris Emerging Drugs SB204: Pelthos Therapeutics SB204, an investigational topical nitric oxide-releasing drug developed by Pelthos Therapeutics, has shown promising efficacy in treating acne vulgaris. This topical monotherapy is designed to address the multi-factorial nature of acne, which involves four key pathophysiological factors: inflammation, bacterial colonization, and other factors. SB204 utilizes the same active pharmaceutical ingredient as berdazimer gel 10.3% and is formulated to provide anti-inflammatory and anti-bacterial activity, making it a potential treatment option for acne patients. B244: AOBiome LLC B244 is a proprietary topical formulation that incorporates a single strain of beneficial AOB, Nitrosomonas eutropha, developed by AOBiome. This patented formulation is designed to restore the skin microbiome by repopulating it with AOBs that are naturally present in the body but often stripped away by most soaps. Once applied to the skin, B244 converts ammonia into nitrite, which exhibits antibacterial properties, and nitric oxide, a signaling molecule that regulates inflammation and vasodilation. Furthermore, this strain of AOB has been shown to reduce inflammatory and pruritic cytokines, such as IL-4, IL-5, IL-13, and IL-31, which are characteristic of atopic responses, thereby providing a comprehensive treatment option for skin conditions. DMT310: Dermata Therapeutics DMT310, developed by Dermata Therapeutics from Spongilla platform technology, is under clinical investigation for the treatment of acne vulagris. The novel product candidate comes from a naturally occurring source of Spongilla lacustris, which has several active ingredients that act by targeting interleukin 17A and 17F. In November 2023, Dermata Therapeutics received an FDA response to its DMT310 Phase II study concentrating on the treatment of medical and cosmetic skin conditions. Currently the drug is being evaluated in Phase III of clinical development for the treatment of acne vulgaris. Discover the future of Acne Vulgaris Treatments with DelveInsight's latest market report. Get expert insights and forecasts—download now! @ Acne Vulgaris Market Drivers and Barriers Acne Vulgaris Market Outlook Effective management of acne requires a comprehensive approach that addresses the underlying factors and incorporates lifestyle modifications, topical treatments, and systemic therapies as needed. The current Acne Vulgaris treatment market for acne vulgaris is driven by the increasing prevalence of acne, rising awareness of skincare, and the need for alternative treatment options. Key developments include a diverse array of topical and systemic therapies, each targeting specific aspects of the complex pathogenesis of this common skin disorder. Topical treatments such as salicylic acid and azelaic acid are used to improve skin moisture, reduce inflammation, and eliminate comedones. Systemic therapies, including oral antibiotics like tetracycline and doxycycline, oral retinoids like isotretinoin, and hormonal agents like spironolactone, are utilized for severe cases. Scope of the Acne Vulgaris Market Report Coverage- 7MM Study Period- 2020-2034 Acne Vulgaris Companies- Galderma Labs, Ortho Dermatologics, Bausch Health, Timber Pharmaceuticals, BioPharmX, Botanix Pharmaceuticals, Kintor Pharma, and others. Acne Vulgaris Therapies- B244, SB204, DMT310, BTX 1503, and others. Acne Vulgaris Therapeutic Assessment: Acne Vulgaris Current Marketed and Acne Vulgaris Emerging Therapies Acne Vulgaris Market Dynamics: Acne Vulgaris market drivers and Acne Vulgaris market barriers Acne Vulgaris Unmet Needs, KOL's views, Analyst's views, Acne Vulgaris Market Access and Reimbursement Explore the dynamics of the Acne Vulgaris Market with DelveInsight. From market size to emerging drugs—find it all in our latest report. Read now! @ Acne Vulgaris Ongoing Clinical Trials Analysis Table of Content 1 Key Insights 2 Report Introduction 3 Acne Vulgaris Epidemiology Overview at a Glance 4 Epidemiology Forecast Methodology 5 Executive Summary 6 Key Events 7 Disease Background and Overview 8 Epidemiology and Patient Population 9 Patient Journey 10 KOL Views 11 Appendix 12 DelveInsight Capabilities 13 Disclaimer 14 About DelveInsight About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
